March 14, 2025

Reduced-Dose Anticoagulants Lower Bleeding, Study Finds

Findings indicate that while non-inferiority was not established, the reduced-dose regimen resulted in fewer bleeding complications without a marked increase in venous thromboembolism (VTE) recurrence.

Conexiant

March 14, 2025

No Increased Cardiovascular Risk with Nicotinamide Use: Study

Analysis of over 13,000 patients across two cohorts found that nicotinamide exposure was not associated with increased risk of major adverse cardiovascular events

Conexiant

March 13, 2025

Multivitamins After MI: Any Benefit for Patients with Diabetes?

The primary endpoint occurred in 35% of both the OMVM and placebo groups, according to a randomized trial evaluating multivitamins in post-MI patients with diabetes.

Conexiant

March 13, 2025

FDA Chief Counsel Resigns Two Days In

U.S. FDA's chief counsel resigns amidst controversy surrounding her appointment and connections to mifepristone during the Biden administration.

Reuters

March 11, 2025

Doctors Never Truly Vacation, Study Reveals

"Organizations should implement strategies to minimize clinical tasks during PTO."

Conexiant

March 10, 2025

BMI Influences Antiplatelet Therapy Outcomes in Patients Who Experienced AMI

Deescalation from ticagrelor to clopidogrel after PCI showed significantly better outcomes in AMI patients with BMI < 28, primarily through reduced bleeding risk

Conexiant

March 06, 2025

An Estimated 31 Million Americans Borrowed for Medical Bills in 2024

A new West Health-Gallup Survey survey reveals insights into medical debt across all income levels and demographics in the United States.

Conexiant

March 06, 2025

Toxic Stress Linked to Higher Cardiovascular Risk in Younger Women

Toxic stress was associated with an increased odds of cardiovascular disease among younger women but not older women, study shows.

Conexiant

March 03, 2025

Type 1 Diabetes Linked to Lower Cardiovascular Event Rate

DM1 was associated with a lower probability of incident cardiovascular events than DM2, finds a new study analyzing over 162,000 patients from the Veradigm Metabolic Registry.

Conexiant